Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0059 | 0.2677 | 0.2677 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0092 | 0.4943 | 1 |
Brugia malayi | Bromodomain containing protein | 0.0074 | 0.3698 | 0.7286 |
Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.1412 | 0.2753 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0022 | 0.0198 | 0.0198 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0022 | 0.0198 | 0.0198 |
Brugia malayi | Bromodomain containing protein | 0.0038 | 0.1249 | 0.1948 |
Mycobacterium tuberculosis | Probable aldehyde dehydrogenase | 0.006 | 0.2745 | 0.5 |
Echinococcus multilocularis | geminin | 0.0167 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0092 | 0.4943 | 0.4943 |
Loa Loa (eye worm) | hypothetical protein | 0.0038 | 0.1254 | 0.2429 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0092 | 0.4943 | 0.4943 |
Loa Loa (eye worm) | hypothetical protein | 0.007 | 0.3413 | 0.6859 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.006 | 0.2745 | 0.5 |
Toxoplasma gondii | aldehyde dehydrogenase | 0.006 | 0.2745 | 0.5 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0035 | 0.1091 | 0.1091 |
Leishmania major | aldehyde dehydrogenase, mitochondrial precursor | 0.006 | 0.2745 | 0.5 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.006 | 0.2745 | 0.5 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.006 | 0.2745 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0092 | 0.4943 | 0.4943 |
Schistosoma mansoni | hypothetical protein | 0.002 | 0.0071 | 0.0071 |
Schistosoma mansoni | bromodomain containing protein | 0.0062 | 0.2916 | 0.2916 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0059 | 0.2677 | 0.2677 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0092 | 0.4943 | 0.4943 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0092 | 0.4943 | 0.4943 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0035 | 0.1091 | 0.1091 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.006 | 0.2745 | 0.2745 |
Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.1539 | 0.3015 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.006 | 0.2745 | 0.2745 |
Schistosoma mansoni | hypothetical protein | 0.0167 | 1 | 1 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0092 | 0.4943 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0167 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0092 | 0.4943 | 0.4943 |
Echinococcus granulosus | aldehyde dehydrogenase mitochondrial | 0.006 | 0.2745 | 0.2745 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0022 | 0.0198 | 0.0198 |
Echinococcus multilocularis | aldehyde dehydrogenase, mitochondrial | 0.006 | 0.2745 | 0.2745 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0092 | 0.4943 | 0.4943 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | = 8.9 uM | Cytotoxicity against human MT2 cells by MTT assay | ChEMBL. | 20304641 |
CC50 (ADMET) | = 12.5 uM | Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay | ChEMBL. | 20304641 |
CC50 (ADMET) | = 15 uM | Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay | ChEMBL. | 20304641 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.